Objectives: The aim of this study was to determine the antimicrobial activities of the combination between colistin and rifampicin against carbapenem-resistant Acinetobacter baumannii.
INTRODUCTION
1 These factors are difficult to improve because most patients are severely ill and they require these devices to maintain their conditions. In addition, these infections are commonly associated with antimicrobial resistant pathogens. 2 Even though carbapenems are the first-line agents in the treatment for severe infections caused by A.
baumannii, this microorganism is developing a resistance to carbapenems as well as to most of the other antimicrobial agents 3 , causing limitations in the treatment. The return to old antimicrobial agents which have remained active to A. baumannii seems to be an alternative way besides the attempt to discover new antimicrobial agents. 4, 5 Recently, colistin has been used in the therapy for patients with infections caused by the multidrugresistant gram-negative bacteria. [6] [7] [8] Rifampicin is especially relevant to staphylococcal or streptococcal skin and soft tissue infections. It is also used in combination therapy for the treatment of Mycobacterium tuberculosis infections and infections related to prosthetic devices. 9 Several previous studies reported that the combination between colistin and rifampicin in vitro showed the synergy effect against multidrugresistant A. baumannii. 10, 11 The bactericidal activity of colistin that interferes with bacterial cell membrane structure causes bacterial cell to leak, and works together with the inhibition of DNA-dependent RNA polymerase of the bacteria by rifampicin. The combined activity enriches the activity of each drug, and each has different mechanisms of action. 12, 13 Although toxicity of colistin is mainly nephrotoxicity, rifampicin has less toxicity and less urinary excretion. 14 The combination therapy along with the reduction in dose of each agent may cause toxicity reduction as compared with the monotherapy and may decrease the evolution of resistance during the treatment.
4,15
The present study aimed to demonstrate the in vitro activities of the combination of colistin and rifampicin against carbapenem-resistant A. baumannii isolates in Thailand. This was accomplished by using MICs determination, synergy and time-kill studies and the observation of cell structure changes after exposure to colistin, rifampicin alone and the combination under scanning electron microscopy. 
MATERIALS AND METHODS

Microorganisms
Synergy study
All isolates were determined for the combined effect of colistin and rifampicin by the checkerboard method according to Pillai, Moellering and Eliopoulos. 17 The range of concentrations used in the study Bactericidal activity was defined as a decrease of at least 3 log 10 CFU/ml in the viable cell counts with respect to the original inoculums (99.9% killing) and bacteriostatic activity was defined as a decrease of less than 3 log 10 CFU/ml in viable cell counts (90-99% killing). The regrowth was defined as an increase of pathogen by at least 2 log 10 CFU/ml after at least 6 hours of incubation.
Statistical analysis
ANOVA was used to compare the BA 24 (Bacteriolytic area for 24 hours). Any value of P below 0.05 was defined as significant.
Morphological changes
Scanning electron microscopy was chosen to 
RESULTS
Susceptibility testing
The antimicrobial susceptibilities of 12 antimicrobial agents against 30 isolates of A. baumannii are shown in Table 1 . All isolates were resistant to meropenem, imipenem and rifampicin. Among these isolates, 33% of them were highly resistant to rifampicin. This resistance was interpreted when the inhibition zone of each drug was less than 10 mm. 18 Results showed that 96.7% of the tested isolates were resistant to cefepime, ceftazidime, piperacillin/tazobactam and ciprofloxacin, while 90%
were resistant to amikacin, gentamicin, netilmicin and tobramycin. None of the isolates was resistant to colistin. Tables 2 and 3 show the MICs of colistin and rifampicin for 30 isolates of A. baumannii. All isolates were resistant to rifampicin (MIC range from 8 to 16 μg/ml; susceptible breakpoint ≤ 1 μg/ml) while 96.7% of tested organisms were susceptible to colistin (MIC range from 1 to 4 μg/ml; susceptible breakpoint ≤ 2 μg/ml). The MICs of colistin at which 50 and 90% of tested isolates were inhibited were1 and 2
μg/ml and of rifampicin were 8 and 8 μg/ml, respectively. baumannii by checkerboard method.
No. of isolates (%)
Resistant
Synergy study
The results of the checkerboard synergy study for all isolates are shown in Similar to the results in the present study, about one third of carbepenem-resistant strains were also highly resistant to rifampicin (inhibition zone < 10 mm).
Colistin is a large molecule which could poorly diffuse on the surface of agar media, so the susceptibility of the drug was done only by agar dilution method which showed that 29 isolates (96.7%) exhibited susceptibility to colistin (susceptible breakpoint ≤ 2 μg/ml). 20 One isolate (3.3%) was resistant to colistin as shown in Tables 2 and 3 . and MIC 90 of the tested isolates for colistin and rifampicin were 1 and 2 μg/ml, and 8 and 8 μg/ml, respectively. The MIC 50 and MIC 90 of colistin and rifampicin observed in this study were higher than those reported by other authors. This shows that the isolates tested in this study were intermediately resistant to rifampicin, while decreasing the susceptibility to colistin.
When the drugs in combination show synergy or additive effect against the tested organisms, it could be suggested that the combination may be used as an Thailand.
